FRI0029 DEVELOPMENT OF AN ALGORITHM FOR THE CLASSIFICATION OF CARDIOVASCULAR COMORBIDITY IN RHEUMATOID ARTHRITIS: DATA FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE. (June 2019)

• Record Type: Journal Article
• Authors: Cui, Kangping; Movahedi, Mohammad; Bombardier, Claire; Kuriya, Bindee
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 675
• Page End: 675
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.2479
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Cardiovascular disease (CVD) is increased in rheumatoid arthritis (RA). The ability to accurately identify CVD and its risk factors is important for primary and secondary prevention strategies. RA registries collect comorbidity data, but discordance between physician-reported and patient-reported comorbidities often exists. Objectives: We aimed to develop an algorithm for the classification of CVD and CVD RF in a representative RA registry. Methods: Data were collected from the Ontario Best-practices Research Initiative (OBRI), a clinical registry of RA patients followed in routine care in Ontario, Canada. Clinical information, including patient medication profile, was obtained at registry entry, through physician visits and patient telephone interviews. Cardiovascular disease (CVD) was defined as having ≥ 1 of myocardial infarction (MI), coronary artery disease (CAD), cerebral vascular accident (CVA, including transient ischemic attack and stroke), or peripheral arterial disease (PAD). CVD risk factors included hypertension (HTN), dyslipidemia (DLD), diabetes mellites (DM), and current smoking. Results: An algorithm for classifying CVD and CVD risk factors was developed including the 2033 subjects with baseline data. At cohort entry, the prevalence of CVD was 5.4% (n=110), HTN 670 (32.9%), DLD 401 (19.7%), DM 165 (8.1%), and current smoking 346 (17%). Seventeen (15.7%) subjects were not identified as having CVD by physician-report but were classified as having CVD upon medication review. Discrepancy between physician and patient-reported CVD RF were: 207 for HTN (31%), 291 for DLD (73%), and 22 for DM (13%). Chart review of 55 patients showed sensitivity of 100% for CVD, 78% for HTN, and 42% for DLD classification. Conclusion: An algorithm for classification of CVD has been successfully developed in a representative RA registry. The discrepancy between physician and patient-reported CVD highlights the importance of utilizing information from multiple sources when classifying comorbidities. Disclosure of Interests: Kangping Cui: None declared, Mohammad Movahedi Employee of: ONTARIO BEST PRACTICE RESEARCH INITIATIVE (OBRI), Claire Bombardier Grant/research support from: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Hospira, Janssen, Merck, Novartis, Pfizer Inc, Sanofi, Speakers bureau: Roche, Bindee Kuriya Consultant for: Advisory Board Member: Abbvie, Sanofi Genzyme, Eli Lilly, Pfizer Canada, Roche